Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia

被引:0
作者
Yong-Pyo Lee
Sang Eun Yoon
Yuqin Song
Seok Jin Kim
Dok Hyun Yoon
Tsai-Yun Chen
Young Il Koh
Ka Won Kang
Ho sup Lee
Kevin Tay Kuang Wei
Soon Thye Lim
Michelle Poon
Cosphiadi Irawan
Weili Zhao
Young Rok Do
Mark Hong Lee
Soo Chin Ng
Won-Sik Lee
Ye Guo
Huilai Zhang
Hye-Jin Kang
Hwan Jung Yun
Hyo Jung Kim
Daryl Tan Chen Lung
Jae-Yong Kwak
Jae Joon Han
Yeung-Chul Mun
Sung Yong Oh
Hyeok Shim
Jung Hye Kwon
Byeong Seok Sohn
Seong Kyu Park
Jae Cheol Jo
Young Hyeh Ko
Zhu Jun
Won Seog Kim
机构
[1] Sungkyunkwan University School of Medicine,Division of Hematology
[2] Peking University Cancer Hospital and Institute,Oncology, Department of Medicine, Samsung Medical Center
[3] University of Ulsan College of Medicine,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma
[4] National Cheng Kung University Hospital,Asan Medical Center
[5] Seoul National University School of Medicine,Department of Internal Medicine, Seoul National University Hospital
[6] Korea University College of Medicine,Division of Hematology and Oncology, Department of Internal Medicine
[7] Kosin University Gospel Hospital,Division of Hematology
[8] Oncocare Cancer Center,Oncology
[9] National Cancer Centre,Department of Haematology
[10] National University Health System,Oncology
[11] Indonesia Cipto Mangunkusumo National Central General Hospital,Division of Hematology and Oncology, Department of Internal Medicine, Dongsan Medical Center
[12] Ruijin Hospital,Department of Hematology
[13] Keimyung University College of Medicine,Oncology
[14] Konkuk University Medical Center,Division of Hemato
[15] Subang Jaya Medical Center,Oncology, Department of Internal Medicine, Busan Paik Hospital
[16] Inje University College of Medicine,Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital
[17] Fudan University Shanghai Cancer Center,Department of Internal Medicine
[18] Tianjin Medical University Cancer Institute and Hospital,Division of Hematology and Oncology, Department of Internal Medicine, Hallym University Sacred Heart Hospital
[19] Korea Institute of Radiological and Medical Sciences,Division of Hematology
[20] Chungnam National University College of Medicine,Oncology, Department of Internal Medicine, Jeonbuk National University Hospital
[21] Hallym University College of Medicine,Department of Hematology and Medical Oncology, College of Medicine
[22] Raffles Cancer Centre,Division of Hematology
[23] Jeonbuk National University,Oncology, Ewha Womans University Mokdong Hospital
[24] Kyung Hee University,Division of Hematology and Oncology, Department of Internal Medicine, Dong
[25] Ewha Womans University,A University Hospital
[26] Dong-A University College of Medicine,Department of Internal Medicine
[27] Wonkwang University School of Medicine, Department of Internal Medicine, Division of Hemato
[28] Hallym University,Oncology, Kangdong Sacred Heart Hospital
[29] Inje University College of Medicine,Department of Internal Medicine, Sanggye Paik Hospital
[30] Soonchunhyang University College of Medicine,Department of Internal Medicine
[31] Ulsan University College of Medicine,Division of Hematology and Oncology, Department of Internal Medicine, Ulsan University Hospital
[32] Sungkyunkwan University School of Medicine,Department of Pathology, Samsung Medical Center
来源
International Journal of Hematology | 2021年 / 114卷
关键词
Lymphoma; T-cell; Cutaneous; Incidence; Therapeutics; Survival; Prognosis;
D O I
暂无
中图分类号
学科分类号
摘要
Cutaneous T-cell lymphomas (CTCLs) are a group of T-cell lymphomas with low incidence. Due to their indolent characteristics, treatment strategies have not yet been established for advanced CTCLs. In this study, relative incidence of CTCLs in Asia was estimated and the therapeutic outcomes presented based on various treatments currently used in clinics for advanced CTCLs. As part of a prospective registry study of peripheral T-cell lymphoma (PTCL) conducted across Asia, including Korea, China, Taiwan, Singapore, Malaysia, and Indonesia, subgroup analysis was performed for patients with CTCLs. Among 486 patients with PTCL, 37 with CTCL (7.6%) were identified between April 2016 and February 2019. Primary cutaneous ALK-negative anaplastic large cell lymphoma (ALCL, 35.1%) was the most common subtype. With a median follow-up period of 32.1 months, median progression-free survival (PFS) was 53.5 months (95% CI 0.0–122.5), and overall survival was not reached. 14 patients (48.2%) underwent subsequent treatment after the first relapse, but the response rate was 20% with a PFS of 2.2 months (95% CI 0.3–4.0). Six patients received autologous stem cell transplantation (auto-SCT). However, auto-SCT did not result in better outcomes. Additional studies are needed on standard care treatment of advanced or refractory and relapsed CTCLs.
引用
收藏
页码:355 / 362
页数:7
相关论文
共 123 条
  • [1] Willemze R(2005)WHO-EORTC classification for cutaneous lymphomas Blood 105 3768-3785
  • [2] Jaffe ES(2019)The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas Blood 133 1703-1714
  • [3] Burg G(2017)T-cell non-hodgkin lymphomas: spectrum of disease and the role of imaging in the management of common subtypes Korean J Radiol 18 71-83
  • [4] Cerroni L(2009)Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases Blood 113 5064-5073
  • [5] Berti E(2015)Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries Cancer Med 4 1440-1447
  • [6] Swerdlow SH(2012)Age, race, sex, stage, and incidence of cutaneous lymphoma Clin Lymphoma Myeloma Leuk 12 291-296
  • [7] Willemze R(2017)Cutaneous T-cell lymphoma Clin Lab Med 37 527-546
  • [8] Cerroni L(2012)Cutaneous T-cell lymphoma in Asians ISRN Dermatol 2012 575120-286
  • [9] Kempf W(2010)Current and emerging treatment strategies for cutaneous T-cell lymphoma Drugs 70 273-1019
  • [10] Berti E(2015)Genomic landscape of cutaneous T cell lymphoma Nat Genet 47 1011-805